BR112022021085A2 - Anticorpos anti-cd89 humano humanizados e usos dos mesmos - Google Patents

Anticorpos anti-cd89 humano humanizados e usos dos mesmos

Info

Publication number
BR112022021085A2
BR112022021085A2 BR112022021085A BR112022021085A BR112022021085A2 BR 112022021085 A2 BR112022021085 A2 BR 112022021085A2 BR 112022021085 A BR112022021085 A BR 112022021085A BR 112022021085 A BR112022021085 A BR 112022021085A BR 112022021085 A2 BR112022021085 A2 BR 112022021085A2
Authority
BR
Brazil
Prior art keywords
salts
steviol glycosides
stevia extract
malonated
steviol
Prior art date
Application number
BR112022021085A
Other languages
English (en)
Inventor
Johannes Simons Petrus
Theodorus Den Hartog Marcel
Boon Louis
Original Assignee
Jjp Biologics Sp Z O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jjp Biologics Sp Z O O filed Critical Jjp Biologics Sp Z O O
Publication of BR112022021085A2 publication Critical patent/BR112022021085A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

MÉTODOS DE TRATAMENTO DE UM EXTRATO DE ESTÉVIA E PARA AUMENTAR O RENDIMENTO DE GLICOSÍDEOS DE ESTEVIOL. Vários aspectos da presente invenção se referem à extração de glicosídeo de esteviol. Um método de tratamento de um extrato de estévia inclui glicosídeos de esteviol e/ou sais dos mesmos, e glicosídeos de esteviol malonados e/ou sais dos mesmos, incluindo tratar o extrato de estévia a um pH maior que 10 para converter pelo menos alguns dos glicosídeos de esteviol malonados e/ou sais dos mesmos em glicosídeos de esteviol não-malonados e/ou sais dos mesmos, para produzir um extrato de estévia modificado. O método inclui diminuir o pH do extrato de estévia modificado até um pH menor que 9 para fornecer um extrato de estévia modificado com pH ajustado. O método inclui também recuperar os glicosídeos de esteviol e/ou sais dos mesmos a partir do extrato de estévia modificado com pH ajustado, os glicosídeos de esteviol e/ou sais dos mesmos recuperados, incluindo os glicosídeos de esteviol não-malonados e/ou sais dos mesmos.
BR112022021085A 2020-04-21 2021-04-21 Anticorpos anti-cd89 humano humanizados e usos dos mesmos BR112022021085A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP20170723 2020-04-21
PCT/NL2021/050259 WO2021215919A1 (en) 2020-04-21 2021-04-21 Humanized anti-human cd89 antibodies and uses thereof

Publications (1)

Publication Number Publication Date
BR112022021085A2 true BR112022021085A2 (pt) 2022-12-27

Family

ID=70390932

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022021085A BR112022021085A2 (pt) 2020-04-21 2021-04-21 Anticorpos anti-cd89 humano humanizados e usos dos mesmos

Country Status (10)

Country Link
US (1) US20230242646A1 (pt)
EP (1) EP4139355A1 (pt)
JP (1) JP2023523919A (pt)
KR (1) KR20230004739A (pt)
CN (1) CN115698078A (pt)
AU (1) AU2021259052A1 (pt)
BR (1) BR112022021085A2 (pt)
CA (1) CA3172618A1 (pt)
MX (1) MX2022013085A (pt)
WO (1) WO2021215919A1 (pt)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US569376A (en) 1896-10-13 Adjustable bracket for transmitters
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6018031A (en) * 1989-10-20 2000-01-25 Trustees Of Dartmouth College Binding agents specific for IgA receptor
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
IL104570A0 (en) 1992-03-18 1993-05-13 Yeda Res & Dev Chimeric genes and cells transformed therewith
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
US6838254B1 (en) 1993-04-29 2005-01-04 Conopco, Inc. Production of antibodies or (functionalized) fragments thereof derived from heavy chain immunoglobulins of camelidae
US5994128A (en) 1995-06-15 1999-11-30 Introgene B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US5693671A (en) 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
JP2006512895A (ja) 2002-06-28 2006-04-20 ドマンティス リミテッド リガンド
EP1844073A1 (en) 2005-01-31 2007-10-17 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
KR20080090406A (ko) 2005-11-28 2008-10-08 젠맵 에이/에스 재조합 １가 항체 및 그의 제조 방법
EP2127666A1 (en) * 2008-05-28 2009-12-02 Drug Discovery Factory B.V. Method for the treatment or prophylaxis of chronic inflammatory diseases
WO2020084056A1 (en) * 2018-10-25 2020-04-30 Swiss Pharma International Ag Anti-human cd89 antibodies and uses thereof

Also Published As

Publication number Publication date
CA3172618A1 (en) 2021-10-28
MX2022013085A (es) 2023-01-11
KR20230004739A (ko) 2023-01-06
EP4139355A1 (en) 2023-03-01
JP2023523919A (ja) 2023-06-08
CN115698078A (zh) 2023-02-03
AU2021259052A1 (en) 2022-12-01
US20230242646A1 (en) 2023-08-03
WO2021215919A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CO2017011245A2 (es) Conjugados proteína-polisacárido de estreptococo grupo b, métodos para producir conjugados, composiciones inmunógenas que comprenden conjugados y sus usos
BRPI0821658B8 (pt) anticorpo monoclonal humano ou um fragmento de ligação ao antígeno do mesmo que se liga a hnkg2d e seus usos
PT1100516E (pt) Extratos de matricaria (tanacetum parthenium) contra doencas inflamatorias
Yendo et al. A rabies vaccine adjuvanted with saponins from leaves of the soap tree (Quillaja brasiliensis) induces specific immune responses and protects against lethal challenge
RS53009B (en) IDENTIFICATION OF TUMOR RELATED ANTIGENS FOR THE TREATMENT OF TREATMENT
BRPI0411906A (pt) compostos, processo para a sua preparação, composições farmacêuticas que compreendem os mesmos, método para tratar ou prevenir uma enfermidade mediada pela ativação da enzima de sintase de glicogênio, e utilização dos compostos
BR112015008418A2 (pt) uso de uma composição imunogênica, composição imunogênica, e, métodos para intensificar atividade opsônica mediada por anticorpo contra um sorotipo alvejado de streptococcus pneumoniae em um indivíduo e para imunizar um hospedeiro humano contra doenças causadas por infecção por streptococcus pneumoniae
BR112021019854A2 (pt) Anticorpos anti-sema3a e seus usos para o tratamento dos olhos ou de doenças oculares
MX2022005903A (es) Métodos para tratar el cáncer de mama her2 positivo con tucatinib en combinación con un conjugado fármaco-anticuerpo anti-her2.
EA201990010A1 (ru) Вакцина против вируса инфекционного бронхита
BR112017005120A2 (pt) composição, conjugado terapêutico isolado, método para tratar câncer em um paciente necessitando do mesmo, método para induzir anticorpos em um indivíduo, composição farmacêutica e método para induzir anticorpos em um indivíduo
BR112022021085A2 (pt) Anticorpos anti-cd89 humano humanizados e usos dos mesmos
BR112022007595A2 (pt) Métodos para tratar doença de alzheimer
BR112022002579A2 (pt) Anticorpos contra ilt2 e uso dos mesmos
BR112022005465A2 (pt) Conjugados de proteína-macromolécula e métodos de uso dos mesmos
CO2023006684A2 (es) Anticuerpos contra sars-cov-2 y usos de los mismos
BR112022021097A2 (pt) Métodos de tratamento de um extrato de estévia e para aumentar o rendimento de glicosídeos de esteviol
BR112022021065A2 (pt) Anticorpos terapêuticos de musk
BR112019005581A2 (pt) método de alívio dos sintomas da síndrome pré-menstrual
MAwOzA et al. Contractile effect of Sclerocarya birrea (A Rich) Hochst (Anacardiaceae)(Marula) leaf aqueous extract on rat and rabbit isolated vascular smooth muscles: cardiovascular topics
BR112022001660A2 (pt) Inibidores de calpaína e usos dos mesmos para o tratamento de distúrbios neurológicos
BR112021019857A2 (pt) Polímero superabsorvente e um método de aumento de teor de açúcar em plantas
SE0303397D0 (sv) Compounds and method for RNA interference
BR112022020012A2 (pt) Composições que compreendem 15-hepe e métodos de tratamento ou prevenção de distúrbios hematológicos e/ou doenças relacionadas
BR112021020049A2 (pt) Planta de estévia, semente, tecido, cultura de tecido ou célula, métodos para produzir uma planta de estévia, um extrato de estévia, um produto purificado de glicosídeo de esteviol, um alimento ou bebida, uma composição adoçante, um sabor ou um medicamento e para selecionar uma planta de estévia, extrato, e, kit